Relaxin: Review of biology and potential role in treating heart failure

Current Heart Failure Reports

Volumn 7, Issue 2, 2010, Pages 75-82

  Teichman, Sam L ^a   Unemori, Elaine ^a   Teerlink, John R ^b   Cotter, Gad ^c   Metra, Marco ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Momentum Research Inc   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; Congestive heart failure; Dyspnea; Pharmacologic therapy; Relaxin; Vasodilation

Indexed keywords

CREATININE; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLYCERYL TRINITRATE; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RELAXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE HEART FAILURE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BLOOD PRESSURE; BLOOD VESSEL TONE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DYSPNEA; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMODYNAMIC MONITORING; HUMAN; KAPLAN MEIER METHOD; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LENGTH OF STAY; NATRIURESIS; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY; PULMONARY ARTERY OCCLUSION PRESSURE; REPERFUSION INJURY; REVIEW; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION; VISUAL ANALOG SCALE; WEIGHT REDUCTION; WOUND HEALING; DRUG EFFECTS; FEMALE; HEART FAILURE; HEMODYNAMICS;

FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; PREGNANCY; RELAXIN; VASODILATION;

EID: 77954623284     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0010-z     Document Type: Review

References (54)

1. Cotter G, Metra M, Milo-Cotter O, et al.: Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008, 10:165-169.
2. • Cotter G, Felker GM, Adams KF, et al.: The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J 2008, 155:9-18. This article provides a broader insight into the pathophysiology of AHF.
3. Colombo PC, Onat D, Sabbah HN: Acute heart failure as "acute endothelitis"-interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008, 10:170-175.
4. Hisaw FL: Experimental relaxation of the pubic ligament of the guinea pig. Proc Soc Exp Biol Med 1926, 23:661-663.
5. Fevold HL, Hisaw FL, Meyer RK: The relaxative hormone of the corpus luteum. Its purification and concentration. J Am Chem Soc 1930, 52:3340-3348.
6. •• Jeyabalan A, Shroff SG, Novak J, et al.: The vascular actions of relaxin. Adv Exp Med Biol 2007, 612:65-87. This article is an extensive review of the vascular biology and pharmacology of relaxin.
7. Schrier RW, Durr JA. Pregnancy: an overfill or underfill state. Am J Kidney Dis 1987, 9:284-289.
8. Baylis C: Relaxin may be the "elusive" renal vasodilatory agent of normal pregnancy. Am J Kidney Dis 1999, 34:1142-1145.
9. •• Dschietzig T, Teichman SL, Unemori E, et al.: Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009, 15:182-190. This phase 1 study provided cardiac hemodynamic proof-ofconcept data for the vasodilatory properties of relaxin.
10. •• Teerlink JRT, Metra M, Felker GM, et al.: Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF). Lancet 2009, 373:1429-1439. This phase 2 study provided encouraging data that relaxin could relieve symptoms in patients with AHF and possibly improve prognosis.
11. Conrad KP, Novak J: Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 2004, 287:R250-R261.
12. Dschietzig T, Bartsch C, Baumann G, et al.: Relaxin-A pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Therapeutics 2006, 112: 38-56.
13. •• Teichman SL, Unemori E, Dschietzig T, et al.: Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009, 14:321-329. This extensive review discusses the vascular biology, pharmacology, and clinical data of relaxin, with a focus on the potential to treat heart failure.
14. Samuel CS, Hewitson TD, Unemori EN, Tang MLK: Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007, 64:1539-1557.
15. Haynes WG, Webb DJ: Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998, 16:1081-1098.
16. Schneider MP, Boesen EI, Pollock DM: Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease. Ann Rev Pharmacol Toxicol 2007, 47:731-759.
17. McMurray JJ, Ray SG, Abdullah I, et al.: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
18. Good JM, Nithoyannopoulos P, Ghatei MP, et al.: Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J 1994, 15:1634-1640.
19. Masson S, Latini R, Anand IS, et al.: The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2006, 12:375-380.
20. Asano K, Bohlmeyer TJ, Westcott JY, et al.: Altered expression of endothelin receptors in failing human left ventricles. J Molec Cell Cardiol 2002, 34:833-846.
21. Bogzil AH, Ashton N: Relaxin-induced changes in renal function and RXFP1 receptor expression in the female rat. Ann N Y Acad Sci 2009, 1160:313-316.
22. Dschietzig T, Richter C, Bartsch C, et al.: The pregnancy hormone relaxin is a player in human heart failure. Faseb J 2001, 15: 2187-2195.
23. Dschietzig T, Bartsch C, Richter C, et al.: Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factorkappaB. Circ Res 2003, 92: 32-40.
24. Danielson LA, Sherwood OD, Conrad KP: Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999, 103:525-533.
25. Unemori EN, Amento EP: Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990, 265:10681-10685.
26. Danielson LA, Conrad KP: Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J Appl Physiol 2003, 95:1509-1514.
27. Debrah DO, Conrad KP, Jeyabalan A, et al.: Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 2005, 46:745-750.
28. Lucas C, Johnson W, Hamilton MA, et al.: Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Amer Heart J 2000, 140:840-847.
29. CostanzoMR, GuglinME, SaltzbergMT, et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Amer Coll Cardiol 2007, 49:675-683.
30. Milo O, Cotter G, Kaluski E, et al.: Inflammatory and neurohormonal activation in cardiogenic pulmonary edema: implications on the pathogenesis and outcome of acute ischemic versus nonischemic acute heart failure. Am J Cardiol 2003, 92:222-226.
31. Teerlink JR, Metra M, Felker GM, et al.: Vasodilators in acute heart failure (AHF): does blood pressure matter? Results from Pre-Relax-AHF. J Cardiac Failure 2009, 15:S74.
32. Smith MC, Danielson LA, Conrad KP, et al.: Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol 2006, 17:3192-3197.
33. Bogzil AH, Eardley R, Ashton N: Relaxin-induced changes in renal sodium excretion in the anesthetized male rat. Am J Physiol Regulatory Integrative Comp Physiol 2005, 288:R322-R328.
34. Erikson MS, Unemori E: Relaxin clinical trials in systemic sclerosis. In Relaxin 2000, Proceedings of the Third International Conference on Relaxin and Related Peptides. Edited by Tragear GW, Ivell R, Bathgate RA, Wade JD. Broome, Australia: Kluwe Academic Publishers; 2000:373-381.
35. Hsu SY, Nakabayashi K, Nishi S, et al.: Activation of orphan receptors by the hormone relaxin. Science 2002, 295:671-674.
36. Kompa AR, Samuel CS, Summers RJ: Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br J Pharmacol 2002, 137:710-718.
37. Samuel CS, Unemori EN, Mookerjee I, et al.: Relaxin modulates cardiac fibroblast proliferation, differentiation and collage production and reverses cardiac fibrosis in vivo. Endocrinology 2004, 145:4125-4133.
38. Bani D, Ballati L, Masini E, et al.: Relaxin counteracts asthmalike reaction induced by inhaled antigen in sensitized guinea pigs. Endocrinology 1997, 138:1909-1915.
39. Masini E, Nistri S, Vannacci A, et al.: Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway. Endocrinology 2004, 145:1106-1112.
40. Santora K, Rasa C, Visco D, et al.: Antiarthritic effects of relaxin, in combination with estrogen, in rat adjuvant-induced arthritis. J Pharmacol Exp Ther 2007, 322:887-893.
41. Dschietzig T, Bartsch C, Stangl V, et al.: Identification of the pregnancy hormone relaxin as a glucocorticoid receptor agonist. FASEB J 2004, 18:1536-1538.
42. Masini E, Bani D, Bello MG, et al.: Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 1997, 138:4713-4720.
43. Bani D, Masini E, Bello MG, et al.: Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Amer J Pathol 1998, 152:1367-1376.
44. Perna AM, Masini E, Nistri S: Human recombinant relaxin reduces heart injury and improves ventricular performance in a swine model of acute myocardial infarction. Ann NY Acad Sci 2005, 1041:431-433.
45. Nistri S, Cinci L, Perna AM, et al.: Mast cell inhibition and reduced ventricular arrhythmias in a swine model of acute myocardial infarction upon therapeutic administration of relaxin. Inflamm Res 2008, 57(Suppl 1):S7-S8.
46. Conrad KP, Debrah DO, Novak J, et al.: Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 2004, 145:3289-3296.
47. Samuel CS, Du XJ, Bathgate RA, Summers RJ: Relaxin the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther 2006, 112:529-552.
48. Van Der Westhuizen ET, Halls ML, Samuel CS, et al.: Relaxin family peptide receptors-from orphans to therapeutic targets. Drug Discov Today 2008, 13:640-651.
49. Lekgabe ED, Kiriazis H, Zhao C, et al.: Relaxin reverses cardiac and renal fibrosis in spontaneous hypertensive rats. Hypertension 2005, 46:412-418.
50. Lekgabe ED, Su Y, McGuane JT, et al.: Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis in mice with fibrotic cardiomyopathy. J Mol Cell Cardiol 2006, 41:739.
51. Danielson LA, Welford A, Harris A: Relaxin improves renal function and histology in aging Munich-Wistar rats. J Am Soc Nephrol 2006, 17:1325-1333.
52. Tozzi CA, Poiani GJ, McHugh NA, et al.: Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat. Pulm Pharmacol Ther 2005, 18:346-353.
53. PeacockWF, De Marco T, Fonarow GC, et al.: Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008, 358:2117-2126.
54. Lewis M, Deshpande U, Guzman L, et al.: Systemic relaxin administration stimulates angiogenic cytokine expression and vessel formation in a rat myocardial infarct model. In Relaxin 2000, Proceedings of the Third International Conference on Relaxin and Related Peptides. Edited by Tragear GW, Ivell R, Bathgate RA, Wade JD. Broome, Australia: Kluwe Academic Publishers; 2000:373-381.